Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Immunodeficiency Diseases01:25

Immunodeficiency Diseases

2.6K
Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...
2.6K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

591
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
591
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

1.0K
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.0K
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

558
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
558
Hypersensitivity Reactions: Cytolytic Reactions01:01

Hypersensitivity Reactions: Cytolytic Reactions

43
Type II hypersensitivity involves IgG and IgM antibodies targeting cell surface antigens, leading to cell destruction. This can occur through complement activation, antibody-dependent cell-mediated cytotoxicity (ADCC), or acting as opsonins for phagocytosis. When excessive, these reactions cause significant tissue damage.Drug-induced hemolytic anemia is a common example, where drugs like penicillin or cephalosporins bind to red blood cells, forming drug-protein complexes. These complexes...
43
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

1.4K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Incidence of bilateral disease and choroidal neovascularisation in punctate inner choroiditis.

The British journal of ophthalmology·2026
Same author

Evidence and Consensus Based Guidelines for Imaging in Tubercular Choroiditis. Multimodal imaging in Uveitis (MUV) Taskforce: Report 17.

Ophthalmology. Retina·2026
Same author

Antiadalimumab Antibodies in Patients With Inflammatory Ocular Diseases: Incidence and Clinical Outcomes.

American journal of ophthalmology·2026
Same author

Evidence and Consensus-Based Guidelines in Vogt-Koyanagi-Harada Disease. Multimodal Imaging in Uveitis (MUV) Taskforce Report 16.

Ophthalmology. Retina·2026
Same author

Deconstructing White Dot Syndromes-Multimodal Imaging in Uveitis (MUV) Taskforce: Report 11.

American journal of ophthalmology·2026
Same author

Evidence and Consensus-Based Imaging Guidelines in Cytomegalovirus Retinitis: Multimodal Imaging in Uveitis (MUV) Task Force - Report 15.

Ophthalmology. Retina·2026
Same journal

Metastasis of Nasopharyngeal Squamous Cell Carcinoma to the Angle.

Ophthalmology·2026
Same journal

Endocrine Mucin-Producing Sweat Gland Carcinoma of Eyelid.

Ophthalmology·2026
Same journal

Multimodal Imaging of Optic Nerve Invasion in Unilateral Retinoblastoma.

Ophthalmology·2026
Same journal

Avacincaptad Pegol Slows Progressive Ellipsoid Zone Degradation/Loss in Eyes With Geographic Atrophy.

Ophthalmology·2026
Same journal

Access to Intravitreal Anti-VEGF Drugs in Persons with Medicare Advantage Compared with Medicare Fee-For-Service.

Ophthalmology·2026
Same journal

Re: Dones et al.: Emergency department use of ocular point-of-care ultrasound and its utility in diagnosis at a tertiary academic medical center (Ophthalmology. 2026;133:720-727).

Ophthalmology·2026
See all related articles

Related Experiment Video

Updated: Feb 22, 2026

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model
07:40

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model

Published on: January 12, 2022

6.2K

Immunosuppression for the Uveitides.

Douglas A Jabs1

  • 1Departments of Ophthalmology and Medicine, Icahn School of Medicine at Mount Sinai, New York, New York.

Ophthalmology
|September 25, 2017
PubMed
Summary
This summary is machine-generated.

Systemic immunosuppression combined with corticosteroids is effective for treating uveitis, preventing ocular complications, and improving vision. This approach is safe for long-term use in managing inflammatory eye diseases.

More Related Videos

Primed Mycobacterial Uveitis PMU as a Model for Post-Infectious Uveitis
10:33

Primed Mycobacterial Uveitis PMU as a Model for Post-Infectious Uveitis

Published on: December 17, 2021

3.2K
Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats
06:30

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats

Published on: May 23, 2025

1.0K

Related Experiment Videos

Last Updated: Feb 22, 2026

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model
07:40

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model

Published on: January 12, 2022

6.2K
Primed Mycobacterial Uveitis PMU as a Model for Post-Infectious Uveitis
10:33

Primed Mycobacterial Uveitis PMU as a Model for Post-Infectious Uveitis

Published on: December 17, 2021

3.2K
Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats
06:30

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats

Published on: May 23, 2025

1.0K

Area of Science:

  • Ophthalmology
  • Immunology
  • Rheumatology

Background:

  • Uveitis encompasses over 30 intraocular inflammatory diseases.
  • Corticosteroids and immunosuppression are common treatments for various uveitis types, including juvenile idiopathic arthritis-associated uveitis, intermediate uveitis, posterior uveitis, and panuveitis.
  • Low-dose oral corticosteroids (<7.5 mg/day) are often ineffective for long-term management.

Purpose of the Study:

  • To compare the effectiveness and safety of systemic therapy (oral corticosteroids and immunosuppression) versus regional corticosteroid treatment for uveitis.
  • To evaluate long-term outcomes and systemic side effects of combined immunosuppressive therapy.
  • To inform initial treatment strategies for noninfectious intermediate, posterior, and panuveitides.

Main Methods:

  • The Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-up Study utilized a randomized comparative effectiveness design.
  • The Systemic Treatment for Eye Diseases (SITE) Cohort Study provided long-term safety data for immunosuppressive agents like antimetabolites and calcineurin inhibitors.
  • Analysis focused on preventing ocular complications, visual outcomes, and systemic side effects.

Main Results:

  • Systemic therapy with oral corticosteroids and immunosuppression demonstrated safety for up to 7 years, comparable to regional corticosteroid therapy, with increased antibiotic use for infections.
  • Long-term safety was suggested for immunosuppressive agents such as antimetabolites and calcineurin inhibitors.
  • Nonalkylating-agent immunosuppression showed a low rate (<10%/year) of sustained drug-free remissions but reduced relapse risk after prolonged treatment.
  • Alkylating agents can induce remissions but may increase cancer risk.

Conclusions:

  • Systemic corticosteroids and immunosuppression are a preferred initial therapy for many noninfectious intermediate, posterior, and panuveitides.
  • Long-term immunosuppression, particularly with antimetabolites or calcineurin inhibitors, appears safe and effective.
  • Biologics, such as adalimumab targeting TNF-α, represent a promising future treatment avenue for noninfectious uveitis.